Respiratory illness in people living with HIV in the era of antiretroviral therapy

Acute respiratory tract illness in an HIV infected population with a high uptake of antiretroviral therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN38386321

Enrollment

140

Registered

2017-04-27

Start date

2015-12-01

Completion date

Unknown

Last updated

2023-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory illness Respiratory Acute respiratory illness

Interventions

All participants will have baseline tests and then be asked to report the frequency of acute respiratory illness over a 12 month period. When participants develop an acute respiratory illness, they wi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HIV-infected cohort: 1. HIV positive 2. Willing to participate in study and able to return for review in the event of respiratory tract infections, and to participate for the duration of the study 3. 18 years or above HIV-uninfected participants: 1. Willing to participate in study and able to return for review in the event of respiratory tract infections, and to participate for the duration of the study 2. 18 years or above 3. Consent to HIV testing 4. Negative HIV test

Exclusion criteria

Exclusion criteria: 1. Unable to participate for the full duration of the study 2. Unable to return for review in the event of respiratory tract infection (for instance those living a long distance from the study site) 3. Current significant acute respiratory tract illness such as pulmonary tuberculosis, Pneumocystis jirovecii pneumonia

Design outcomes

Primary

Measure	Time frame
The annual incidence of acute respiratory illness in HIV positive compared to HIV negative participants is measured over 12 months of follow-up with weekly contacts to participants.	—

Secondary

Measure	Time frame
1. Duration of symptoms during respiratory tract illness in HIV infected and uninfected participants is measured by participant diaries completed daily during acute respiratory illness 2. Health-related quality of life measured by the St Georges Respiratory Questionnaire and EuroQoL-5D at baseline 3. Healthcare resource utilisation arising from acute respiratory illness during acute respiratory tract illness measured using participant daily diaries 4. The prevalence of positive microbial isolation in throat swabs and sputum samples at baseline 5. The prevalence of positive microbial isolation during acute respiratory illness in throat swabs and sputum samples 6. The baseline prevalence of obstructive lung disease is measured by pre-bronchodilator spirometry at baseline	—

Measure

Time frame

1. Duration of symptoms during respiratory tract illness in HIV infected and uninfected participants is measured by participant diaries completed daily during acute respiratory illness 2. Health-related quality of life measured by the St Georges Respiratory Questionnaire and EuroQoL-5D at baseline 3. Healthcare resource utilisation arising from acute respiratory illness during acute respiratory tract illness measured using participant daily diaries 4. The prevalence of positive microbial isolation in throat swabs and sputum samples at baseline 5. The prevalence of positive microbial isolation during acute respiratory illness in throat swabs and sputum samples 6. The baseline prevalence of obstructive lung disease is measured by pre-bronchodilator spirometry at baseline

—

Countries

England, United Kingdom

Contacts

Public ContactJames Brown

james.brown.14@ucl.ac.uk+44 20 7794 0500 extension 34304

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 18, 2026